Abstract: The present invention relates to bicyclic heteroaromatic urea or carbamate compounds of formula I where the variables are as defined in the claims and the description. The invention moreover relates to a pharmaceutical composition containing these compounds I, and to these compounds for use in therapy, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization.

Abstract: The present invention relates to a pharmaceutical composition comprising a compound of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof; to the compound of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof for use as a medicament, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization, and to certain novel compounds of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to compounds of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing such compounds; and to said compounds of the formula I or a tautomer or a pharmaceutically acceptable salt thereof for use as a medicament, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization, wherein X1 is CR1 or N; X2 is CR2 or N; X3 is CR3 or N; X4 is CR4 or N; Y1 is N, NR5a, S, O or CR5b; Y2 is N, NR5c, S, O or CR5d; Z is N or C; with the proviso that at most two of X1, X2, X3 and X4 are N; with the proviso that Y1 is not O if Y2 is CR5d and simultaneously Z is C; with the proviso that Y1 and Y2 are not both simultaneously O or S; with the proviso that at least one of Y1, Y2 and Z is a heteroatom or heteroatom-contai

Abstract: The present invention relates to benzofuran ureas or carbamates of formula I and heteroaromatic analogues thereof as described below or a tautomer or a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing these compounds, and to these compounds for use in therapy, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization. Formula (I) wherein X1 is CR1 or N; X2 is CR2 or N; X3 is CR3 or N; X4 is CR4 or N; with the proviso that at most two of X1, X2, X3 and X4 are N; E1 is O or NR6a; E2 is O or NR6b; with the proviso that E and E2 are not simultaneously O; L1 is a bond, optionally substituted C1-C6-alkylene or C3-C8-cycloalkylene; L2 is a bond, optionally substituted C1-C6-alkylene, C3-C8-cycloalkylene, etc.